Denali Capital Extends Deadline on Longevity Biomedical Deal

Denali Capital Acquisition said $50,000 was deposited into its trust to extend the deal deadline by another month to April 11. The SPAC has a merger agreement with Longevity Biomedical, which is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.” 

Redemptions have removed most of the SPAC’s trust, although Longevity Biomedical in August agreed to waive the deal’s $30 million cash closing condition. Denali also has an $18 milion PIPE commitment with FutureTech Capital to support the transaction.

The deal was announced in January 2023. Read more.

Total
0
Shares
Related Posts
Read More

Aurora Prices $220M IPO

The SPAC intends to focus its search for a target with operations or prospects in the Europe, Middle East and Africa Technology and Media industry, including data analytics, enterprise software, security software, e-commerce and online marketplaces, and/or financial services technology.